CGRP Receptor Antagonism in COVID-19: Potential Cardiopulmonary Adverse Effects

Recently, the US FDA has authorized a drug repurposing trial with calcitonin gene-related peptide (CGRP) receptor antagonists to reduce lung inflammation in coronavirus 2019 (COVID-19). However, the well-established cardiopulmonary protective effects of CGRP raise concerns about the safety of antago...

Descripción completa

Detalles Bibliográficos
Autores principales: Skaria, Tom, Wälchli, Thomas, Vogel, Johannes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Forum
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7580524/
https://www.ncbi.nlm.nih.gov/pubmed/33129692
http://dx.doi.org/10.1016/j.molmed.2020.10.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7580524/
https://www.ncbi.nlm.nih.gov/pubmed/33129692
http://dx.doi.org/10.1016/j.molmed.2020.10.005

Ejemplares similares